BDTX Live signals | Maximize Profits with Getagraph.com

BUY 103428 min ago

@ $4.67

Issued: 14 Feb 2024 @ 13:53

Return: 18.84%

Previous signal: Feb 13 - 15:50

Previous signal: Sell

Return: 11.73 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 10:41):

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors...

Stats
Today's Volume	124 256
Average Volume	651 393
Market Cap	287.03M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.440 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.95
ATR14	$0.0260 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Campbell Shannon	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Raman Prakash	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Campbell Shannon	Buy	0
2024-04-10	Raman Prakash	Buy	0
2024-03-15	Behbahani Ali	Buy	3 166	Common Stock

INSIDER POWER
98.85
Last 97 transactions
Buy: 11 965 700 \| Sell: 275 000

Volume Correlation

Long: 0.27 (neutral)

Short: -0.42 (neutral)

Signal:(64.559) Neutral

Black Diamond Correlation

10 Most Positive Correlations
SVAC	0.972
RMRM	0.952
TLGT	0.926
ACST	0.919
PXLW	0.916
FEYE	0.898
BLZE	0.877
IMAB	0.877
VVOS	0.877
TMTS	0.875

10 Most Negative Correlations
AMRB	-0.962
NETE	-0.958
MMAC	-0.951
GOODM	-0.903
GLADL	-0.898
SRAC	-0.881
QELL	-0.878
ROCR	-0.874
LWAC	-0.872
RAVN	-0.864

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Black Diamond Correlation - Currency/Commodity

0.86
( strong )

0.90
( strong )

0.00
( neutral )

0.92
( very strong )

0.00
( neutral )

-0.82
( strong negative )

Black Diamond Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2023
Revenue:	$0
Gross Profit:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2022
Revenue:	$0
Gross Profit:	$-3.24M (0.00 %)
EPS:	$-2.33

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.00347

Financial Reports:

No articles found.

Black Diamond

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.